FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Bibliothèque de peptides

Semax

ACTH 4-10 analog / Heptapeptide Semax

Cognitive & Neuro

Semax is a synthetic heptapeptide analog of the ACTH(4-10) fragment, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a neuroprotective and nootropic agent. It is approved in Russia and Ukraine for the treatment of stroke, transient ischemic attacks, cognitive disorders, optic nerve atrophy, and peptic ulcers. Semax enhances BDNF expression, modulates serotonergic and dopaminergic neurotransmission, and provides neuroprotection without any hormonal (adrenocorticotropic) activity despite its ACTH-derived structure.

Mécanisme d'action

Synthetic analog of ACTH 4-10 fragment with a Pro-Gly-Pro C-terminal extension. Increases BDNF and NGF expression in the hippocampus. Enhances attention, memory, and learning without hormonal effects of full-length ACTH. Neuroprotective against oxidative stress.

Protocoles de recherche

Pour des fins de recherche uniquement. Pas de conseil médical.

Research protocols use 200-600mcg intranasally 2-3 times daily. Russian approved protocols use 0.1% or 1% nasal drops. Higher concentrations (1%) used for acute neuroprotection. Typical cycles are 2-4 weeks.

Notes de recherche

Clinical Research Status

Semax has been approved in Russia since 2001 as a nasal spray (0.1% and 1% solutions) for acute ischemic stroke, cognitive impairment, and optic nerve diseases. Large-scale Russian clinical trials involving stroke patients demonstrated reduced neurological deficit scores and improved functional outcomes when administered within 6 hours of ischemic events. It has not entered FDA regulatory pathways and remains unapproved in Western markets. The 1% formulation (N-Acetyl Semax Amidate, or NASA) is used in more severe neurological conditions while the 0.1% is used for cognitive enhancement.

Key Published Findings

A 2005 study in Doklady Biological Sciences showed Semax increased BDNF mRNA expression in the rat hippocampus and basal forebrain by 1.4-3x baseline within 24 hours. Clinical stroke trials published in Zhurnal Nevrologii i Psikhiatrii demonstrated 2.4x faster neurological recovery versus controls when administered acutely. Semax was shown to differentially regulate 24 genes in glial cells related to neuroinflammation and neuroprotection in a 2013 transcriptomics study. Research confirms no adrenocorticotropic effects despite the ACTH backbone, as the melanocortin-receptor binding motif was deliberately excluded from the fragment.

Safety Profile

Extensive clinical use in Russia over 20+ years has revealed no significant adverse effects, hormonal disruption, or organ toxicity. Semax produces no sedation, tolerance, withdrawal, or dependence, and no drug-related deaths have been reported. The peptide is rapidly degraded by aminopeptidases with a plasma half-life of approximately 2 minutes, though CNS effects persist for 20-24 hours due to intracellular signaling cascades. Nasal administration avoids first-pass metabolism and achieves CNS penetration without systemic accumulation.

Drug Interactions & Contraindications

No formally documented drug interactions exist in published literature, though the serotonergic modulation suggests theoretical caution with SSRIs or MAOIs at high doses. Contraindicated in patients with acute psychosis or severe manic episodes due to its stimulating cognitive effects. May theoretically potentiate the effects of stimulant medications (amphetamines, methylphenidate) through dopaminergic enhancement. Not recommended in pregnancy due to insufficient safety data despite the absence of hormonal activity.

Comparison to Related Compounds

Semax is more stimulating and neuroprotective compared to Selank, which is primarily anxiolytic; Russian clinicians frequently prescribe them together for complementary effects. Unlike racetam nootropics, Semax has a well-defined mechanism (BDNF upregulation, TrkB signaling) and documented neuroprotective efficacy in stroke. Compared to cerebrolysin (another Russian-approved neuroprotective), Semax offers non-invasive nasal administration versus required IV infusion. The N-Acetyl Semax Amidate (NASA) analog offers approximately 60x greater stability and potency versus unmodified Semax.

Community Observations

Users report enhanced verbal fluency, motivation, and mental clarity typically within 10-30 minutes of intranasal administration, lasting 4-8 hours. The 0.1% solution (50 mcg/drop) is most commonly used at 2-3 drops per nostril, 2-3 times daily for cognitive enhancement. Some users report a mild stimulant-like quality that can interfere with sleep if dosed too late in the day. Combining Semax with Selank is considered the gold-standard peptide nootropic stack in the biohacking community, providing focused cognition without anxiety.

Moitié de vie

~2-3 minutes (intranasal effects last 4-6 hours)

Réconstitution

Bacteriostatic water (BAC) for SubQ; saline for nasal

Conservation

Lyophilisé

Refrigerate 2-8C up to 12 months.

Réconstitué

Refrigerate 2-8C. Use within 14 days.

Statut légal aux États-Unis

Research chemical (approved in Russia)

Autres noms connus

ACTH 4-10 analogHeptapeptide Semax

Questions fréquentes

Qu'est-ce que Semax ?

Semax is a synthetic heptapeptide analog of the ACTH(4-10) fragment, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a neuroprotective and nootropic agent. It is approved in Russia and Ukraine for the treatment of stroke, transient ischemic attacks, cognitive disorders, optic nerve atrophy, and peptic ulcers. Semax enhances BDNF expression, modulates serotonergic and dopaminergic neurotransmission, and provides neuroprotection without any hormonal (adrenocorticotropic) activity despite its ACTH-derived structure.

Comment agit Semax ?

Synthetic analog of ACTH 4-10 fragment with a Pro-Gly-Pro C-terminal extension. Increases BDNF and NGF expression in the hippocampus. Enhances attention, memory, and learning without hormonal effects of full-length ACTH. Neuroprotective against oxidative stress.

Quel est le statut réglementaire de Semax aux États-Unis ?

Research chemical (approved in Russia)

Quelle est la demi-vie de Semax ?

~2-3 minutes (intranasal effects last 4-6 hours)

Sous quels autres noms Semax est-il connu ?

ACTH 4-10 analog, Heptapeptide Semax

Peptide Contacts fournit des résumés basés sur la recherche à des fins d’information uniquement. Nous ne hébergeons, n’épandons ni ne recommandons les documents des fournisseurs. Toutes les certificats d'analyse, certificats GMP et communications du fournisseur doivent être demandés et vérifiés directement par l'acheteur. Rien sur cette plateforme ne constitue un avis juridique, médical ou professionnel. Les utilisateurs sont entièrement responsables de la vérification des informations du fournisseur et de l’assurance de la conformité avec toutes les lois locales, d'état et fédérales applicables avant l'achat de tout produit chimique de recherche. L'utilisation de cette plateforme constitue l'acceptation pleine et entière de la responsabilité personnelle.

Lire la déclaration complète